QNCX — Quince Therapeutics, Inc.
Quince Therapeutics, Inc. (QNCX) operates as a biopharmaceutical firm dedicated to developing targeted treatments for debilitating and rare diseases. A cornerstone of their innovation is an extensive bone-targeting drug delivery platform, engineered to accurately transport diverse therapeutic agents, such as small molecules, peptides, and large molecules, directly to affected bone areas like fractures and disease sites. Leading their pipeline is NOV004, an anabolic peptide meticulously designed to pinpoint and accumulate its therapeutic action precisely at bone fracture locations. The company, previously known as Cortexyme, Inc., officially rebranded as Quince Therapeutics, Inc. in August 2022. Established in 2012, Quince Therapeutics is headquartered in South San Francisco, California.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ Global Select
- Employees: 36
- Website: https://www.quincetx.com
Latest SEC filings for QNCX
- 3 — 2026-10-19
- 3 — 2026-10-19
- SCHEDULE 13G — 2026-10-14
- S-8 — 2026-10-08
- EFFECT — 2026-08-25
- SCHEDULE 13G — 2026-08-14
- SCHEDULE 13G — 2026-08-14
- SCHEDULE 13G/A — 2026-08-14
- S-3/A — 2026-08-05
- S-3 — 2026-07-31
Latest QNCX news
- — Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease (GlobeNewswire Inc.)
- — Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript (seekingalpha.com)
- — Quince Therapeutics, Inc. (QNCX) Discusses LAM-001 Clinical Progress in Pulmonary Hypertension and Bronchiolitis Obliterans Syndrome Transcript (seekingalpha.com)
Educational tool only — not investment advice.